There is no single pill that works for women the way Viagra works for men, but two FDA-approved medications do exist for women with persistently low sexual desire. The reason there’s no direct equivalent comes down to biology: Viagra increases blood flow to the penis, solving a largely mechanical problem. For most women experiencing sexual dysfunction, the issue originates in the brain rather than in blood flow, so the treatments target different systems entirely.
Why Viagra Itself Doesn’t Work for Most Women
Researchers have actually tested sildenafil (the active ingredient in Viagra) in women. A 12-week study of 202 postmenopausal women found that it did improve genital sensation and satisfaction during sex compared to placebo. But there was a major catch: it only worked for women whose sole issue was physical arousal. Women who also had low desire saw no benefit at all.
That distinction matters because low desire is far more common than isolated arousal problems in women. When desire is the missing piece, increasing blood flow to the genitals doesn’t address the root cause. The brain simply isn’t sending the signals that make a person want sex in the first place. This is why the two approved medications for women both work on brain chemistry rather than circulation.
Addyi: A Daily Pill for Low Desire
Addyi (flibanserin) was approved by the FDA in 2015 and is sometimes called “female Viagra” in the media, though it works nothing like Viagra. It acts on serotonin and dopamine receptors in the brain, adjusting the balance between chemicals that inhibit sexual desire and those that promote it. You take it as a daily pill at bedtime, and it typically takes several weeks of consistent use before any effect becomes noticeable.
In clinical trials, women taking Addyi experienced roughly one additional satisfying sexual encounter per month compared to those on placebo. That number sounds modest, but the trials also measured desire itself and personal distress about low libido, and both improved. The medication is approved for premenopausal women under 65 with what’s formally called hypoactive sexual desire disorder (HSDD), meaning persistently low desire that causes real distress and isn’t explained by relationship problems, another medical condition, or a medication side effect.
The biggest practical concern with Addyi is its interaction with alcohol. In safety testing, combining even two glasses of wine with Addyi caused severe drops in blood pressure in about 17% of participants, with some needing medical intervention. The FDA labeling lists alcohol as a contraindication, meaning you need to avoid drinking entirely while taking it. Common side effects on their own include dizziness, sleepiness, and nausea, which is why the pill is taken at bedtime.
Vyleesi: An As-Needed Injection
Vyleesi (bremelanotide) was approved in 2019 and works differently from Addyi in both mechanism and timing. Instead of a daily pill, it’s a self-administered injection given at least 45 minutes before anticipated sexual activity. You inject it under the skin of your abdomen or thigh using a pre-filled autoinjector, similar to devices used for allergy medications.
Vyleesi activates melanocortin receptors in the brain, a pathway involved in sexual arousal and desire. It’s approved for the same population as Addyi: premenopausal women with HSDD. The on-demand format appeals to women who prefer not to take a daily medication, though the injection itself can be a barrier.
Nausea is the most commonly reported side effect, and it can be significant enough that some women stop using it. The nausea tends to be worst after the first few injections and may lessen with continued use. Vyleesi can also cause temporary darkening of the skin, particularly in women with darker complexions, and it may raise blood pressure briefly after injection.
How These Compare to Viagra’s Simplicity
Part of Viagra’s cultural status comes from how straightforward it is. A man takes a pill, blood flow increases, and the physical response follows within 30 to 60 minutes. The effect is dramatic and immediate. Neither Addyi nor Vyleesi offers that kind of experience.
Addyi requires weeks of daily use before results appear, and the improvement in desire is gradual rather than acute. You won’t feel a sudden surge of wanting after taking a dose. Vyleesi is closer to the on-demand model, but it requires an injection, takes at least 45 minutes, and the effects are subtler than what Viagra delivers for erections. Both medications produce real, measurable benefits, but neither feels like flipping a switch.
This gap reflects a genuine biological difference. Erections are a vascular event that responds reliably to increased blood flow. Sexual desire involves a complex web of neurotransmitters, hormones, psychological state, and context. There may never be a single pill that boosts female desire as reliably as Viagra boosts erections, because the underlying process is fundamentally more complex.
Testosterone as an Off-Label Option
No testosterone product is FDA-approved for women, but low-dose testosterone therapy is used off-label for postmenopausal women with low desire. In 2021, the International Society for the Study of Women’s Sexual Health published clinical guidelines for how healthcare professionals should prescribe testosterone to postmenopausal women with HSDD, reflecting growing acceptance of the practice. The guidelines were published simultaneously in three academic journals, signaling broad expert consensus.
Testosterone plays a role in sexual desire for all genders, and levels drop naturally after menopause. The doses used for women are a fraction of what men take, typically delivered through compounded creams or gels applied to the skin. When it works, many women notice an increase in spontaneous sexual thoughts and responsiveness. Blood levels need to be monitored periodically to avoid side effects like acne, unwanted hair growth, or changes in cholesterol.
Which Option Fits Which Situation
If you’re premenopausal and your primary complaint is that you rarely or never feel desire for sex, and that bothers you, Addyi and Vyleesi are the two approved options. Addyi suits women who prefer a daily routine and can commit to avoiding alcohol. Vyleesi suits women who want something occasional and don’t mind self-injection.
If you’re postmenopausal, testosterone therapy may be worth discussing with a provider, particularly if low desire coincided with menopause. Addyi and Vyleesi were not studied in postmenopausal women and are not approved for that group.
If your concern is more about physical arousal (difficulty with lubrication or sensation) than about desire itself, the situation is different. Topical estrogen, lubricants, or other approaches may be more relevant, since the approved HSDD medications specifically target the “wanting” side of sexual function rather than the physical response. The old sildenafil research suggests that Viagra-type drugs could help a narrow subset of women with purely physical arousal issues, but no version has been approved for that use.